Sarepta stock dropped again Wednesday after the FDA announced it's investigating the deaths of two patients who received Elevidys.

Brokerage H.C. Wainwright on Wednesday opined that there will be” little intrinsic value” in Sarepta Therapeutics (SRPT) if ...

In one of the first major tests of the new FDA leadership’s regulatory philosophy toward gene therapies for rare diseases, ...

The FDA is investigating two deaths in non-ambulatory Duchenne muscular dystrophy patients who received a Sarepta gene ...

Duchenne muscular dystrophy is characterized by a mutation in the DMD gene that leads to a lack of dystrophin and muscle loss ...

Elevidys has been given full approval to treat ambulatory patients with DMD, with an accelerated approval in non-ambulatory ...

Sarepta reported a second death in a patient who had received its gene therapy, which raised concerns about the safety and ...

Sarepta has issued a safety update regarding Elevidys (delandistrogene moxeparvovec-rokl) following a second reported case of acute liver failure resulting in death.

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

Breast milk is widely recognized as the gold standard for infant nutrition. It supplies the perfect balance of fats, proteins ...

Discover 5 widely-used supplements that can cause silent liver damage. Learn the hidden risks of popular health products affecting millions daily.

Q. Monsoon often triggers a spike in gastrointestinal infections. What are the most common liver-related complications observed during the season and how can th ...